Market Forecast News: Nuclear Medicine Software to Hit $1,491.55M by 2030
The report "Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030"global nuclear medicine software market will grow to USD 1,491.55 million by 2030 from USD 970.03 million in 2025, at a CAGR of 9.0% from 2025 to 2030.
Browse 540 market data Tables and 58 Figures spread through 464 Pages and in-depth TOC on "Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/nuclear-medicine-software-market-212176442.html
The major factors driving market growth are the increasing prevalence of chronic diseases, technological advancements, automation, cloud deployment, and rising stakeholder investments. Additionally, there is a growing emphasis on real-world data, advanced image analysis, and personalized therapeutic solutions. However, the market's growth is constrained by several challenges related to data security, insufficient training datasets for AI integrations, interoperability between existing systems, and inadequate healthcare infrastructure.
The market growth is influenced by advancements in targeted diagnostics and therapeutic approaches, including personalized treatment methods. Progress in technologies such as image analysis and quantification, advanced analytics, PACS integration, workflow management, data integration, and cloud-native platforms is gradually enhancing imaging accuracy, operational efficiency, and treatment planning. These technological advancements are helping to streamline complex clinical workflows and support decision-making processes.
The diagnostics segment held the major application market share in 2024.
By application, the nuclear medicine software market has been segmented into diagnostic, therapeutics, emergency & stat workflows, and clinical research. Among these, the diagnostics segment commanded the largest market share, which can be attributed to the widespread use of PET and SPECT imaging across various therapeutic areas, including oncology, cardiology, and neurology. Diagnostic imaging serves as the foundational base for nuclear medicine. Growing patient awareness and the increasing demand for early disease detection drive segment growth over the forecast period. Radiology departments are integrating software solutions for image acquisition, reconstruction, quantification, and automated interpretation while making significant investments in PACS integration and AI/ML integrated diagnostic platforms. Furthermore, the surge in cancer screening programs in developed markets and the clinical need for multi-modality image fusion are boosting the growth of diagnostic applications. Lastly, patient-centric reimbursement frameworks across North America and European countries for diagnostic imaging has further contributed to the segment's growth.
The pharmaceutical & biotechnology companies segment is the fastest-growing end-user market segment during the forecast period.
The nuclear medicine software market has been segmented by end users into healthcare providers, pharmaceutical & biotechnology companies, medtech companies, and other end users. Among these, the pharmaceutical & biotechnology companies segment accounted for the largest market share due to the expansion of theranostics and radiopharmaceutical R&D. These companies use nuclear medicine software solutions for clinical trial imaging, personalized dosimetry, and treatment response analytics. Globally, the targeted radiotherapeutics pipeline is expanding and requires advanced software solutions for regulatory-compliant image analysis, data management, and multi-center trial data harmonization. As nuclear medicine becomes integral to precision oncology drug development, software adoption among pharmaceutical and biotech companies is expected to accelerate significantly.
North America dominated the global nuclear medicine software market in 2024.
The nuclear medicine software market has been segmented by region into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Among these, North America is dominant due to the availability of advanced healthcare infrastructure, significant adoption of imaging technologies, and strong regulatory and reimbursement frameworks. Furthermore, the US and Canada have a large installed base of PET and SPECT systems and are readily adopting AI-integrated imaging platforms, cloud-based PACS, and dosimetry planning software. The expanding use of theranostics in cancer treatment—especially for prostate and neuroendocrine tumors—and strong collaborations between hospitals, academic centers, and pharmaceutical companies further fuel the demand for software in both diagnostics and therapeutics. In addition, North America hosts a substantial number of clinical trials for radiopharmaceuticals, which positively impacts the region’s growth. Lastly, the presence of leading market players such as GE Healthcare, Siemens Healthineers, and Philips is boosting the market growth.
The report profiles key players such as GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG (Germany), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Brainlab AG(Germany), Mirada Medical(UK), DOSIsoft SA(France), Hermes Medical Solutions (Sweden), INVIA, LLC (US), and Canon Medical Systems Corporation (Japan).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Nuclear Medicine Software Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
